WC
CRBP icon

Wexford Capital’s Corbus Pharmaceuticals CRBP Stock Holding History

Wexford Capital’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,400
Closed -$81.8K – 262
2025
Q1 		$81.8K Sell
15,400
-29,621
-66% -$261K 0.02% 207
2024
Q4 		$531K Sell
45,021
-23,535
-34% -$395K 0.08% 97
2024
Q3 		$1.41M Buy
68,556
+24,400
+55% +$1.25M 0.34% 56
2024
Q2 		$2M Buy
+44,156
New +$1.86M 0.51% 37
2021
Q1 		– Sell
-852
Closed -$32K – 231
2020
Q4 		$32K Buy
+852
New +$31.9K 0.01% 292

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $310M AUM 37.86% 1-Year Est. Return

Wexford Capital's CRBP Position: Q2 2025 in Review

Wexford Capital sold out of Corbus Pharmaceuticals (CRBP) in Q2 2025, closing a stake of 15,400 shares — an estimated $81.8K sold.

Wexford Capital first reported a position in CRBP in Q4 2020 and held it in 5 quarters. The position peaked at $2M in Q2 2024. 80 funds tracked by Wall St. Rank hold CRBP as of Q2 2025.

  • Wexford Capital reported no remaining Corbus Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Wexford Capital sold 15,400 Corbus Pharmaceuticals shares in Q2 2025, an estimated $81.8K.
  • Wexford Capital first reported a position in Corbus Pharmaceuticals in Q4 2020 and held it in 5 quarters.
  • Wexford Capital's Corbus Pharmaceuticals position peaked at $2M in Q2 2024.
  • 80 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2025.

Based on Wexford Capital's 13F filing for Q2 2025, filed 14 Aug 2025.